CSL's new CEO has big shoes to fill

Past returns generated for shareholders will be tough to match.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The new Chief Executive Officer (CEO) of biotech CSL (ASX: CSL), Mr Paul Perreault, officially took over the reins from his predecessor Dr Brian McNamee on 1 July.

The shareholder returns generated by CSL while under McNamee's watch were nothing short of outstanding. Between 1990 and 2013 while McNamee was at the helm, the annual total shareholder return was 25.9%. That's one tough act to follow!

In his first interview since taking the top job Perreault spoke with the Australian Financial Review. If there was one message to take away from the story it was 'commercialisation', indeed the words 'commercial' and 'commercialisation' were used eight times in the AFR's profile of Perreault.

Having spent hundreds of millions of dollars on research and development, Perrault is charged with taking CSL's R&D portfolio and maximising value through commercialisation. Pleasingly for shareholders Mr Perreault looks to have shareholder wealth creation front and centre in his mind — a trait and culture passed on by Dr McNamee — this was highlighted by Perreault's mention that China is no pushover as a market to enter.

Perreault has been with CSL since 2004, so he already has nearly a decade of experience working within the company, primarily in the USA. His elevation to CEO also involved a handover period from McNamee that lasted nearly one year.

Great management is a key ingredient for companies that succeed in creating significant shareholder value. Other recent 'changing of the guards' where there are big shoes to fill include Fantastic Furniture (ASX: FAN), where founder and executive director Mr Julian Tertini has moved to a non-executive role, and Seven Group (ASX: SVW) where Mr Peter Gammell has resigned and been replaced by former Woodside Petroleum (ASX: WPL) MD and CEO Mr Don Volte AO.

The Australian Financial Review says "good quality Australian shares that have a long history of paying dividends are a real alternative to a term deposit." Get "3 Stocks for the Great Dividend Boom" in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Tim McArthur owns shares in Fantastic Furniture.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »